XFOR NASDAQ
X4 Pharmaceuticals, Inc.
1W: +7.6%
1M: +7.6%
3M: -18.8%
YTD: -16.4%
1Y: -14.5%
3Y: -86.8%
5Y: -97.8%
$3.25
+0.00 (+0.00%)
Weekly Expected Move ±10.4%
$3
$3
$3
$4
$4
Credit Risk of going bust: higher than 73% of companies Debt: 19.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.10 (down 97%), X4 Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $77.2M against a stock market value of $322.2M.
Distance to default 3.19 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $38.4M (short-term plus half of long-term), stock volatility 72.2%; Altman Z'' -3.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.10 (down 97%), X4 Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $77.2M against a stock market value of $322.2M.
Distance to default 3.19 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $38.4M (short-term plus half of long-term), stock volatility 72.2%; Altman Z'' -3.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-03-19
Earliest Filing
2025-06-23
Latest Filing
investor: 6
licensee: 1
Counterparties (Filed by XFOR)
7 relationshipsCompanies named in XFOR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Lincoln Park Capital Fund, LLC | — | investor | Investor entering into a purchase agreement to acquire up to $40,000,000 worth of X4 Pharmaceuticals common stock. | 2025-06-23 | View |
| Norgine Pharma UK Limited | — | licensee | Granted exclusive license to distribute, market, sell, and manufacture mavorixafor in specific territories. | 2025-01-13 | View |
| BCLS II Investco, LP | — | investor | Private placement investor purchasing common stock and pre-funded warrants | 2022-03-03 | View |
| Bain Capital Life Sciences | — | investor | Affiliate of the primary investor BCLS II Investco, LP | 2022-03-03 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Investor entering into a purchase agreement to acquire up to $50,000,000 worth of common stock from X4 Pharmaceuticals, | 2022-01-14 | View |
| BCLS II Investco, LP | — | investor | Investor in a private placement of pre-funded warrants for $10.0 million. | 2021-11-05 | View |
| Abingworth Bioventures 8 LP | — | investor | Institutional accredited investor participating in private placement and option agreement for potential co-development. | 2021-03-19 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-08 | Material Agreement; Termination of Agreement; Financial Obligation; Unregistered Equity Sales; Regul | Agreement | View |
| 2026-09-09 | Other Events; Exhibits | View | |
| 2026-09-08 | Other Events; Exhibits | View | |
| 2026-07-01 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-05-13 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-12 | Officer/Director Change; Shareholder Vote | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-27 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-09-17 | Costs Associated with Exit or Disposal Activities; Departure/Election of Directors; Appointment of O | View | |
| 2025-08-25 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-13 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-08-12 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Departure/Electio | Agreement | View |
| 2025-06-23 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-06-11 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-01 | Results of Operations and Financial Condition; Regulation FD Disclosure | View | |
| 2025-04-24 | Amendments to Articles of Incorporation or Bylaws; Other Events; Financial Statements and Exhibits | View | |
| 2025-04-18 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-03-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-03 | Other Events | View | |
| 2025-02-06 | Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure; Financial Statements an | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR